HEALTHCARE

The Israeli company's treatment is a delayed-release antibiotic administered in the area where the patient has undergone surgery.

Investors highlighted challenges and strategic models in life sciences funding, in a forum co-hosted by Lipa Meir & Co.

The company sees revenue from its leading products doubling to $5 billion by 2030.

The Israeli pharmaceutical company's debt at the end of the first quarter of 2025 was $16.7 billion, after the company repaid $1.4 billion in debt during the quarter.

Over the past 15 years, Israeli startups have been applying Big Data to cure the US healthcare system’s ills. How do they do it, and can they maintain their advantage?

Somite AI is building DeltaStem, a platform and foundation model designed to revolutionize the production of human cells.

Pharma companies everywhere have been hit by the US president's announcement that he will cut prices of drugs to their lowest prices globally.

Market sources believe that the rate of layoffs in Israel will be similar to the general rate worldwide.

The Israeli pharmaceutical company's 3,000 layoffs will help the company achieve its targets for growth and higher profitability.

The Israeli pharmaceutical company unexpectedly announced the layoffs after publishing its first quarter results.

The donation, from Blackstone president Jon Gray and his wife Mindy, will enable the university's Faculty of Medical and Health Sciences to expand both in medical studies and research.

The FDA has ruled that SELARSDI, which Teva has launched with Alvotech, is interchangeable with Stelara for treating adult and pediatric psoriatic arthritis and plaque psoriasis, as well as Crohn's disease, and ulcerative colitis.

In the commercialization deal, Spanish pharmaceutical company Ferrer will receive the rights to market the drug in Europe, while the US market will remain in Prilenia's hands.

The UK pharmaceutical giant is teaming with Tel Aviv University and the Meuhedet and Leumit health funds on the project.

Healthee’s benefits and care navigation platform empowers employees and employers to make the most of their health benefits.

Personal experience motivated Roy Goldenberg to become Israel director of TOM Tikkun Olam Makers. "TOM will be one of the biggest organizations to come out of Israel," he says.

The death of a cancer patient spurred Dr. Adi Zoref-Lorenz into developing the OHI index, which allows the diagnosis of the HLH side effect from cancer immunotherapy, based on two blood tests.

The company, which produces food ingredients in yeast without genetic engineering, cannot pay its debts and is seeking a buyer.

Insightec COO and general manager Eyal Zadicario tells "Globes" about himself and the Israeli ultrasound company's long battle to change the medical world.

Navina equips clinicians and care teams with real-time, data-driven insights that improve the quality of care and financial outcomes.

"We know nothing about the female reproductive system," says Dr. Ola Gutzeit of Rambam Hospital. She seeks to change that, and hence change IVF for the better.

The nine startups participated in the Dangoor HealthTech Academy, a program that connects Israeli startups with the UK healthcare system.

In an exclusive interview Richard Burke talks about the murder of the company's CEO, Donald Trump, his love for Israel, and investment in Israeli startup Korro AI.

Prof. Yifat Merbl of the Weizmann Institute and her team have found a natural source of anti-microbial substances in the "garbage can" of human cells.

In Israel for IATI's MIXiii International Life Science and Health-Tech week, the US investor talks about his life science portfolio and the opportunities Israel must seize.

85% of the senior figures in venture capital funds in Israel's biomed sector see investments by companies and foreign funds increasing in 2025 compared with 2024.

The US medical device company will pay up to $540 million for the Rehovot-based intravascular ultrasound device developer for treating high blood pressure.

Last year "Newsweek" ranked Sheba Medical Center in ninth place and previously it was in tenth place.

Richard Francis said that the question is no longer whether Teva will survive but whether it can grow more.

The Israeli pharmaceutical company's debt fell to $17.8 billion at the end of 2024, down from $19.8 billion at the end of the 2023.